文献速递脊柱关节炎

胃肠-风湿整合诊疗助力IBD相关脊柱关节炎实现关节-肠道双缓解:SPIB真实世界队列四年结果

The role of integrated gastro-rheumatological care in IBD-associated Spondyloarthritis in achieving joint-gut remission: Four-year outcomes from the real-world SPIB cohort.
PubMed 文献 · Semin Arthritis Rheum · 2026-06-03

SPIB真实世界队列纳入159例炎症性肠病相关脊柱关节炎(SpA-IBD)患者,在多学科胃肠-风湿联合门诊管理。基线时肠道与关节同时缓解者仅0.6%,6个月升至5.7%,4年达26.3%;随访中TJC、SJC、LEI、DAPSA、ASDAS、CDAI、pMayo等指标均改善,2年内bDMARD治疗增加36%、糖皮质激素使用减少35%。男性为缓解的预测因素,中轴病变与附着点炎为负性预测因素。

要点

  • 多学科胃肠-风湿联合管理下,SpA-IBD患者关节-肠道双缓解比例4年升至26.3%。
  • 2年内bDMARD治疗增加36%、糖皮质激素使用减少35%。
  • 男性预测缓解(OR 2.80),中轴病变与附着点炎为负性预测因素。

核心结论

  • 胃肠-风湿紧密协作实施关节-肠道双缓解策略对SpA-IBD患者具有长期价值。

研究设计与样本

  • SPIB为真实世界队列,连续纳入在多学科胃肠-风湿联合门诊评估的SpA-IBD患者159例,随访4年。

主要发现

  • 基线时仅0.6%患者达到肠道与关节同时缓解,6个月为5.7%,4年为26.3%。
  • 4年时TJC变化-3.8、SJC变化-1.0、LEI评分变化-0.3。
  • 4年时DAPSA缓解状态增加36.0%,ASDAS inactive disease状态增加38.0%。
  • 4年时CDAI缓解状态增加19.3%,pMayo缓解状态增加26.2%。
  • 2年内bDMARD治疗增加36%,糖皮质激素使用减少35%。

关键数值与推荐

  • 队列中58%为克罗恩病、42%为溃疡性结肠炎。
  • 基线时56%为中轴型SpA-IBD,44%为外周型SpA-IBD。
  • 主要终点为4年时肠道与关节双域同时缓解的比例。

临床怎么用

  • 对SpA-IBD患者可采用风湿与消化科联合门诊模式,以关节-肠道双缓解为目标并长期随访。
  • 中轴病变或附着点炎患者缓解可能性较低,需更密切监测与治疗调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spondyloarthritis associated with inflammatory bowel disease (Spa-IBD) often requires a customised multidisciplinary approach. The aim of this study was to evaluate long-term outcomes of a cohort of SpA-IBD patients with a multidisciplinary management. METHODS: Consecutive patients with SpA-IBD were assessed at our multidisciplinary Gastro-Rheumatological Clinic and enrolled in the SPIB (SpA in Inflammatory Bowel Disease) cohort. The primary endpoint was the proportion of patients achieving remission in both intestinal and articular domains at four years. Secondary outcomes included the cohort's baseline clinical features, progressive improvement in disease activity scores, treatment patterns, and predictors of remission. RESULTS: The cohort includes 159 patients (58% Crohn's disease, 42% ulcerative colitis). At baseline, 56% of patients were diagnosed with axial SpA-IBD, and 44% with peripheral SpA-IBD. At baseline, 0.6% of patients were in combined intestinal and articular remission, and this proportion gradually increased to 5.7% at six months and 26.3% at four years. Clinical outcomes at 4 years included improvements in TJC (Δ-3.8), SJC (Δ-1.0), LEI score (Δ-0.3), DAPSA remission status (+36.0%), ASDAS inactive disease status (+38.0%), and remission status for CDAI (+19.3%) and pMayo (+26.2%) scores. At 2 years, bDMARD therapy increased by 36%, while corticosteroid use decreased by 35%. In multivariable analysis, male gender predicted remission during follow-up (OR 2.80, 95% CI 1.21-6.76), whereas axial disease (OR 0.41, 0.17-0.96) and enthesitis (OR 0.26, 0.11-0.59) were negative predictors. CONCLUSIONS: The long-term results of the SPIB cohort highlight the value of close collaboration between rheumatologists and gastroenterologists in the application of joint-gut remission strategies.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Paci V, Marchionni G, Zabotti A, et al. The role of integrated gastro-rheumatological care in IBD-associated Spondyloarthritis in achieving joint-gut remission: Four-year outcomes from the real-world SPIB cohort. Semin Arthritis Rheum. 2026. PMID: 42276008. doi:10.1016/j.semarthrit.2026.153005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。